TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $161,709 | $141,148 | $120,856 | $108,185 |
| % Growth | 14.6% | 16.8% | 11.7% | – |
| Cost of Goods Sold | $28,155 | $18,938 | $15,541 | $15,399 |
| Gross Profit | $133,554 | $122,210 | $105,315 | $92,786 |
| % Margin | 82.6% | 86.6% | 87.1% | 85.8% |
| R&D Expenses | $40,878 | $31,782 | $46,362 | $23,874 |
| G&A Expenses | $0 | $55,585 | $50,331 | $38,963 |
| SG&A Expenses | $63,311 | $55,585 | $50,331 | $38,963 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $104,189 | $87,367 | $96,693 | $62,837 |
| Operating Income | $29,365 | $34,843 | $8,622 | $29,949 |
| % Margin | 18.2% | 24.7% | 7.1% | 27.7% |
| Other Income/Exp. Net | -$3,456 | -$3,923 | -$3,154 | -$4,496 |
| Pre-Tax Income | $25,909 | $30,920 | $5,468 | $25,453 |
| Tax Expense | -$364,986 | $2,733 | $408 | $2,122 |
| Net Income | $390,895 | $28,187 | $5,060 | $23,331 |
| % Margin | 241.7% | 20% | 4.2% | 21.6% |
| EPS | 2.688 | 0.19 | 0.035 | 0.16 |
| % Growth | 1,314.8% | 450.7% | -78.4% | – |
| EPS Diluted | 2.428 | 0.17 | 0.031 | 0.15 |
| Weighted Avg Shares Out | 145,417 | 146,740 | 146,678 | 145,243 |
| Weighted Avg Shares Out Dil | 160,998 | 162,559 | 162,769 | 160,244 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6,721 | $6,716 | $6,757 | $7,061 |
| Depreciation & Amortization | $62 | $59 | $56 | $62 |
| EBITDA | $32,692 | $37,695 | $12,281 | $32,576 |
| % Margin | 20.2% | 26.7% | 10.2% | 30.1% |